<code id='63565BC08F'></code><style id='63565BC08F'></style>
    • <acronym id='63565BC08F'></acronym>
      <center id='63565BC08F'><center id='63565BC08F'><tfoot id='63565BC08F'></tfoot></center><abbr id='63565BC08F'><dir id='63565BC08F'><tfoot id='63565BC08F'></tfoot><noframes id='63565BC08F'>

    • <optgroup id='63565BC08F'><strike id='63565BC08F'><sup id='63565BC08F'></sup></strike><code id='63565BC08F'></code></optgroup>
        1. <b id='63565BC08F'><label id='63565BC08F'><select id='63565BC08F'><dt id='63565BC08F'><span id='63565BC08F'></span></dt></select></label></b><u id='63565BC08F'></u>
          <i id='63565BC08F'><strike id='63565BC08F'><tt id='63565BC08F'><pre id='63565BC08F'></pre></tt></strike></i>

          
          WSS
          Red Blood Cells
          Adobe

          The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

          The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

          advertisement

          Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          Wikipedia